TOKYO, October 8, 2024 /PRNewswire/ — The company Ciconia Bioventures Inc. (Managing Director, Founder CEO: Toshio Fujimoto“Ciconia”) today announced its establishment as a joint venture based on a major agreement signed April 22, 2024 with Takeda Pharmaceutical Company (NYSE:) Limited (TSE: 4502/NYSE: TAK, President and CEO, Christopher Weber“Takeda”), Company Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura“Astellas”), and Sumitomo Mitsui (NYSE: ) Bank Corporation (President and CEO: Akihiro Fukutome“SMBC”). (The news release about the main deal is here.)
Ciconia seamlessly integrates the entire process from initial drug discovery research to biotech startups, with the goal of translating new technologies and drug discovery programs from biotech. Japan in clinical applications. Using a wide variety of promising drug discovery seeds from Japanese academics, biotech startups, and pharmaceutical companies, the company will focus on developing development strategies and acquiring new data to improve the value of these seeds, turning them into potentially more powerful assets in larger quantities. chances of success. The company will also mobilize additional R&D capital and experienced management teams to launch new initiatives, increasing the number of successful biotech projects from Japan. To achieve these goals of developing new drug discovery programs from Japan in the global pharmaceutical market, to include globally competitive drug discovery technologies, and to promote commercialization, Ciconia incubation activities will be carried out in collaboration with academia, biotechnology ventures, and pharmaceutical companies across the globe. Japanin a shared effort to unlock the potential of global drug discovery.
“Ciconia will test growth stage seeds, establish its own company based on selected seeds, raise funds globally and pursue global product development,” it said. Toshio FujimotoManaging Director, Founder and CEO at Ciconia. “In the end, we hope to bring new things from Japan in the world for our work.”
“The establishment of Ciconia is an important step for continued growth Japanese drug discovery that will lead global R&D,” it said Yasushi KajiiHead of R&D region of Japan at Takeda. “Using our extensive experience in supporting commercial companies and entrepreneurs at home and abroad, we are committed to supporting startups from Ciconia with the best drug discovery seeds to expand globally.”
“We really expect that Ciconia will work Japanese drug discovery ecosystem in collaboration with many players from industry, government, and academia, and bring new treatments to patients around the world through its global growth,” said. Issei TsukamotoPh.D., Head of Business Development, Astellas. “We will provide comprehensive support to Ciconia based on our drug discovery and business expertise, as well as the networks we cultivate around the world.”
“We will support you Japanese to renew by stimulating the development of new technologies and industries through use The company Ciconia Bioventures Inc.which helps in the development of new medicines,” added the SMBC representative.
About The company Ciconia Bioventures Inc.
Location:
- Headquarters: 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-0012, Japan
- In Tokyo Office: 3-11-5, Nihonbashi-Honcho, Chuo-ku, In Tokyo 103-0023, Japan
Established: August 2024
Capital: Approx 600 million yen (including capital reserve)
Management team:
- Managing Director, Founder CEO: Toshio Fujimoto
- COO/CBO: Masaharu Tani
- Interim CSO: Yoshinori Ikeura
Homepage:
